John R. Pollard, M.D.

Our Experts

Back to all Experts
John R. Pollard, M.D.

John R. Pollard, M.D.

Director, ChristianaCare Epilepsy Center

Expertise & Research Interests

  • Epilepsy Clinical Trials
  • Drug Resistant Epilepsy
  • Epilepsy Biomarkers


  • Residency, Neurology, Hospital of the University of Pennsylvania
  • MD, University of Pennsylvania School of Medicine

John R. Pollard, M.D.

Director, ChristianaCare Epilepsy Center

John R. Pollard is a neurologist who specializes in epilepsy, which affects 2.3 million adults and nearly 500,000 children in the United States.


of 09


Downloadable Images and Links
Media Appearances

His seizure sparked terrifying fall that uncovered long-sought answer

2022-10-15 , The Washington Post
“I remember him saying, ‘I can’t believe this happened in front of my family,’ ” recalled his longtime neurologist John R. Pollard, formerly associate director of the epilepsy center at the University of Pennsylvania. Pollard had warned Caldwell that his intractable seizures, which had proved resistant to numerous medications, placed him at risk for sudden death or serious injury.

Evogen's Cognizance Biomarkers Presents Data Showing Its Proteomic Biomarkers Have the Potential to Monitor Seizure Burden to Aid in Epilepsy Patient Management

2019-05-28 , BioSpace
John Pollard, MD, who is an inventor of the Cognizance Biomarkers technology, a practicing neurologist, Director of the Christiana Care Epilepsy Center and Adjunct Associate Professor of Neurology at the University of Pennsylvania's Perelman School of Medicine, commented, "Epilepsy diagnosis can be difficult and slow, with misdiagnosis and suboptimal treatment too often taking years to correct. We undertook development of a proteomic-based blood test to provide an accurate, objective and rapid alternative. Cognizance's first product, the EvoScoreDXTM test, has demonstrated the potential to identify epileptic seizures with excellent sensitivity and specificity. This approach has now been expanded to allow for the accurate monitoring of therapy-associated improvements in the frequency of seizures, which should make it easier to optimize treatment over the lifecycle of the condition."

First in-Patient Adult Epilepsy Monitoring Unit Opens in Delaware

2018-06-20 , Newswise
“We want to help patients who believe they have been over-diagnosed or under-diagnosed so they can see improvement in their lives,” said Neurologist John R. Pollard, M.D., medical director of the new EMU.
Selected Papers and Publications

Association of Epileptic and Nonepileptic Seizures and Changes in Circulating Plasma Proteins Linked to Neuroinflammation

2021-01-25 , Neurology
To develop a diagnostic test that stratifies epileptic seizures (ES) from psychogenic nonepileptic seizures (PNES) by developing a multimodal algorithm that integrates plasma concentrations of selected immune response-associated proteins and patient clinical risk factors for seizure.

Trends in oral anticoagulant co-prescription with antiepileptic drugs among adults with epilepsy, 2010-2018

2020-11-24 , Epilepsy Behavior
Treatment considerations for epilepsy patients requiring anticoagulation are changing, and actual prescribing practices have not been characterized.

The Impact of COVID-19 on Epilepsy Care: A Survey of the American Epilepsy Society Membership

2020-09-17 , Epilepsy Currents
The COVID-19 pandemic has impacted the delivery of care to people with epilepsy (PWE) in multiple ways including limitations on in-person contact and restrictions on neurophysiological procedures.

Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089)

2019-07-10 , Neurology
To evaluate the effect of cenobamate in patients with photoparoxysmal-EEG response (PPR) to intermittent photic stimulation (IPS) as proof of principle of efficacy in patients with epilepsy.

Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants

2019-07-03 , Epilepsia
Treatment options for seizure clusters are limited; the need for easy-to-administer treatments remains. The Staccato system delivers drug deep into the lung via inhalation.

Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy

2010-04-22 , Epilepsia
We report a multicenter, double‐blind, randomized trial of bilateral stimulation of the anterior nuclei of the thalamus for localization‐related epilepsy.
External Service and Affiliations
  • American Board of Psychiatry and Neurology
  • American Board of Clinical Neurophysiology

Biomarkers and methods for detection of seizures and epilepsy

2017-07-13 , WO2017120166A1
Epileptic seizures are difficult to diagnose and are often difficult to distinguish from several conditions with similar presentations, and therefore, diagnosis of seizures is often a long, expensive, and unreliable process.